Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDV2209 first-in-human multiple-ascending-dose trial in subarachnoid haemorrhage
2024-514590-22-00Phase 2Completed
- Sponsor
- Edvince
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing EDV2209 multiple-ascending-dose with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2022; status: completed.
02
Drugs
U0126
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-514590-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514590-22-00.